PureTech Health (LON:PRTC) Trading Up 14.2% - Here's What Happened

Key Points

• PureTech Health plc shares increased by 14.2%, closing at GBX 121.50 ($1.64), with significant trading volume of over 9 million shares, up 1,053% from its average daily volume.
• The company has a market capitalization of £293.65 million and a high price-to-earnings ratio of 714.71, indicating a potentially overvalued stock.
• Insider Bharatt Chowrira recently purchased 167,739 shares at an average cost of GBX 1, signaling insider confidence in the company's future prospects.

Shares of PureTech Health plc (LON:PRTC - Get Free Report) rose 14.2% during mid-day trading on Saturday . The stock traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares changed hands during trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Price Performance

The firm has a market cap of £303.07 million, a price-to-earnings ratio of 737.65 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The stock has a 50-day moving average price of GBX 129.31 and a 200 day moving average price of GBX 129.65.

Insider Activity

In other PureTech Health news, insider Bharatt Chowrira bought 167,739 shares of the business's stock in a transaction dated Thursday, July 3rd. The shares were acquired at an average cost of GBX 1 per share, with a total value of £1,677.39. Company insiders own 13.13% of the company's stock.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.